Van ECK Associates Corp Has $5.38 Million Stake in Repligen Co. (NASDAQ:RGEN)

Van ECK Associates Corp lessened its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 13.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,160 shares of the biotechnology company's stock after selling 6,025 shares during the quarter. Van ECK Associates Corp owned 0.07% of Repligen worth $5,384,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Andra AP fonden bought a new position in shares of Repligen in the 2nd quarter valued at about $25,000. Lazard Asset Management LLC increased its position in Repligen by 206.1% during the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock worth $36,000 after buying an additional 136 shares during the last quarter. UMB Bank n.a. raised its stake in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after buying an additional 130 shares during the period. Blue Trust Inc. lifted its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after buying an additional 127 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter worth about $33,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Ratings Changes

RGEN has been the subject of several research reports. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price objective for the company. Benchmark reiterated a "hold" rating on shares of Repligen in a research report on Monday, August 5th. UBS Group lowered their price target on shares of Repligen from $205.00 to $185.00 and set a "buy" rating on the stock in a research report on Wednesday, July 31st. JPMorgan Chase & Co. increased their target price on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Wednesday, July 31st. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $190.25.

Repligen Trading Down 1.5 %

RGEN stock traded down $2.23 during midday trading on Friday, hitting $141.65. The stock had a trading volume of 174,686 shares, compared to its average volume of 652,728. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.93 billion, a P/E ratio of -3,511.25, a price-to-earnings-growth ratio of 4.19 and a beta of 0.96. The business has a fifty day moving average price of $141.77 and a two-hundred day moving average price of $145.51. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13.

Insider Activity

In other Repligen news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.